Evaluation of the effects of Ellagic acid on inflammation and insulin resistance in patients with Type 2 diabetes mellitus and acute coronary syndrome
Phase 3
Recruiting
- Conditions
- Type 2 diabetes mellitus.Type 2 diabetes mellitus
- Registration Number
- IRCT20220516054874N14
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Patients with type 2 diabetes mellitus
Patients with a history of myocardial infarction according to the American College of Heart criteria
At least 6 months have passed since the diagnosis of diabetes
Age more than 18 years old
Consent to admission to the study
Patients with fasting serum glucose levels greater than or equal to 125 mg/dl
Patients with glycosylated hemoglobin blood levels greater than or equal to 6.5%
Exclusion Criteria
Type 1 diabetes
Kidney failure and GFR<30
Severe liver failure with liver enzymes three times more than normal
Chronic inflammatory disease such as lupus
Pregnancy
Breastfeeding
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in Homeostatic Model Assessment (HOMA-IR). Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.
- Secondary Outcome Measures
Name Time Method